In collaboration with researchers at Vancouver Prostate Centre in Canada, Glactone Pharma has discovered a novel way of enhancing the effects of current prostate cancer treatments. The research,…
Oncorena Holding AB today announces that the company through a share issue has raised capital to build its organization and resources in preparation for clinical development with a patient study of a…
The Danish Medicines Agency and the Ethics Committee in Region Sjaelland have both given Trophea Development approval to initiate the first clinical study, a Phase I study, with an innovative…
Oncorena AB announces that a new full-time CEO has been appointed effective July 1.
Lars Grundemar will lead the company in the intense development phase ahead.
On July 1, 2018 Fredrik Lindgren will assume the position of Chief Business Officer (CBO) at PULS. In his new role Fredrik will work with strategic and operational business development of the PULS portfolio, as well as contribute with support to the development of the individual project companies.
Glactone Pharma, in collaboration with researchers from Karolinska Institutet and Lund University, has been awarded a SEK 1,000,000 (approx. USD 115,000) grant from Swelife and Medtech4health. Glactone Pharma’s project, STAT3 inhibition as immunotherapy for the treatment of prostate cancer, aims to investigate the mechanism behind the combination effect of STAT3 inhibition and immunotherapy.